Wed, May 18, 9:00 AM, Zacks
Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
Thu, May 12, 3:43 PM, Zacks
Bristol-Myers/AbbVie Empliciti Gets Approved in the EU
Bristol-Myers (BMY) and AbbVie (ABBV) have announced the EU approval of Empliciti in combination with Revlimid and dexamethasone, for the treatment of multiple myeloma.